Long-term chelation therapy with deferasirox: Effects on cardiac iron overload measured by T2* MRI

Clinical Drug Investigation

Volumn 30, Issue 4, 2010, Pages 267-273

  Ruffo, Giovan Battista ^a   Borsellino, Zelia ^a   Cuccia, Liana ^a   Marocco, Maria Rita ^a   Gagliardotto, Francesco ^a   Tarantino, Rossana ^a  

^a UOC Ematologia Emoglobinopatie   (Italy)

Author keywords

Beta thalassaemia; Chelating agents, therapeutic use; Deferasirox, therapeutic use; Treatment

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON;

ADULT; ALLOIMMUNIZATION; AMENORRHEA; ARTICLE; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DELAYED PUBERTY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; IRON OVERLOAD; IRON THERAPY; LONG TERM CARE; MALE; MONITORING; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; SHORT STATURE; SPLENECTOMY; THALASSEMIA MAJOR; TRANSFUSION; TREATMENT DURATION;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; TIME FACTORS; TRIAZOLES; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 77949551471     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11534480-000000000-00000     Document Type: Article

References (30)

1. Cunningham MJ, Nathan DG. New developments in iron chelators. Curr Opin Hematol 2005; 12 (2): 129-134
2. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107 (9): 3733-3737
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89 (10): 1187-1193
4. Wood JC. Cardiac iron across different transfusiondependent diseases. Blood Rev 2008; 22 Suppl. 2: S14-21
5. McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009; 13 (1): iii-iv, ix-xi, 1-121
6. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107 (9): 3738-3744
7. Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev 2008; 22 Suppl. 2: S35-41
8. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107 (9): 3455-3462
9. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91 (10): 1343-1351
10. Pathare A, Taher A, Daar S. Deferasirox (Exjade-) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 2010; 89 (4): 405-409
11. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orallyadministered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91 (7): 873-880
12. Stumpf JL. Deferasirox. Am J Health Syst Pharm 2007; 64 (6): 606-616
13. Garbowski M, Eleftheriou P, Pennell D, et al. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox [abstract 116]. Blood 2008; 11: 112
14. PennellD, Porter J, CappelliniM, et al. Efficacy and safety of deferasirox (Exjade-) in reducing cardiac iron in patients with b-thalassemia major: results from the cardiac substudy of the EPIC trial [abstract 3873]. Blood 2008; 11: 112
15. Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety of deferasirox (Exjade-) in preventing cardiac iron overload in b-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trial [abstract 3874]. Blood 2008; 11: 112
16. Wood J, Thompson A, Paley C, et al. Deferasirox (Exjade-) monotherapy significantly reduces cardiac iron burden in chronically transfused b-thalassemia patients: an MRI T2* study [abstract 3882]. Blood 2008; 11: 112
17. Vermylen C. What is new in iron overload? Eur J Pediatr 2008; 167 (4): 377-381
18. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. EurHeart J 2001; 22 (23): 2171-2179
19. Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 14-34
20. Pepe A, Positano V, Santarelli MF, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23 (5): 662-668
21. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006; 76 (3): 183-192
22. Sironi M, Lombardi M, Pepe A, et al. Study of heart function. Milan: Springer-Verlag, 2005
23. Positano V, Pepe A, Santarelli MF, et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed 2007; 20 (6): 578-590
24. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105 (4): 539-542
25. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging 2007; 25 (6): 1147-1151
26. Berdoukas V, Chouliaras G, Moraitis P, et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11 (1): 20
27. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115 (14): 1876-1884
28. Porter J, Tanner T, Pennell D, et al. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox) [abstract 3600]. Blood 2005; 11: 106
29. Wood J, Thomson AA, Paley C, et al. MRI T2* demonstrates reduced cardiac iron burden following moderate to high-dose deferasirox treatment in chronically transfused beta-thalassemia patients [abstract]. Haematologica 2008; 93 (1)
30. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29 (5): 909-917